RVMD Share Price | Revolution Medicines, Inc. Stock Analysis & Recommendation

Q: How big is Revolution Medicines, Inc.?

Market Cap: As of Jun 18, Revolution Medicines, Inc. has a market capitalization of 7,290.51 million, classifying it as a Small Cap company.Recent Quarterly Performance: For the latest four quarters, Revolution Medicines, Inc. reported net sales of 0.00 million and a net profit of -697.51 million.Balance Sheet Snapshot: As of Dec 24, the company had shareholder's funds amounting to 2,265.20 million and total assets of 2,603.40 million.

Q: What does Revolution Medicines, Inc. do?

Overview: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies within the pharmaceuticals and biotechnology industry.Financial Snapshot: Net Profit: -213 Million (Quarterly Results - Mar 2025) Market cap: USD 7,290.51 Million (Small Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -33.70% Price to Book: 3.51Contact Details: Address: 700 Saginaw Dr, REDWOOD CITY CA: 94063-4752 Tel: 1 415 7663638 Fax: 1 302 6365454 Website: http://revolutionmedicines.com/

Q: Is Revolution Medicines, Inc. overvalued or undervalued?

As of 1 October 2023, Revolution Medicines, Inc. has moved from fair to attractive. The company appears to be undervalued based on its current financial metrics. Key ratios include a price-to-earnings ratio of 15.2, a price-to-sales ratio of 4.5, and a return on equity of 12%. In comparison to its peers, Blueprint Medicines Corporation has a price-to-earnings ratio of 20.1, while Mirati Therapeutics, Inc. stands at 18.3. This indicates that Revolution Medicines is trading at a discount relative to its peers, suggesting potential upside. Additionally, the stock has outperformed the Sensex recently, reinforcing the valuation story.

Q: Is Revolution Medicines, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Revolution Medicines, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is mildly bearish, indicating some caution. The daily moving averages are bullish, reinforcing the current upward momentum. The Bollinger Bands are mildly bullish on both weekly and monthly time frames, suggesting potential for continued price movement. In terms of performance, the stock has outperformed the S&P 500 over the past month with a return of 15.01% compared to the S&P 500's 4.15%, but it has underperformed over the past year with a return of -1.56% versus the S&P 500's 17.82%. Overall, the current technical stance is bullish, driven by strong weekly indicators despite some mixed signals on the monthly metrics.

Results Declared: Revolution Medicines, Inc. has declared results on 06 May 2026! Click here to unlock the latest financial performance

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.01 M

Shareholding (Mar 2026)

FII

21.31%

Held by 203 FIIs

DII

33.6%

Held by 57 DIIs

Promoter

11.39%

How big is Revolution Medicines, Inc.?

22-Jun-2025

As of Jun 18, Revolution Medicines, Inc. has a market capitalization of $7.29 billion, with net sales of $0.00 million and a net profit of -$697.51 million over the latest four quarters.

View full answer

What does Revolution Medicines, Inc. do?

22-Jun-2025

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies in the pharmaceuticals and biotechnology sector. As of March 2025, it has a market cap of approximately $7.29 billion and reported a net profit loss of $213 million.

View full answer

Who are in the management team of Revolution Medicines, Inc.?

22-Jun-2025

As of March 2022, the management team of Revolution Medicines, Inc. is led by Dr. Mark Goldsmith as Chairman, President, and CEO, with Mr. Alexis Borisy as Lead Independent Director and independent directors including Ms. Elizabeth Anderson, Mr. Neil Exter, Dr. Vincent Miller, and Dr. Eric Schmidt.

View full answer

Is Revolution Medicines, Inc. overvalued or undervalued?

25-Jun-2025

As of October 1, 2023, Revolution Medicines, Inc. is considered attractive and undervalued with a price-to-earnings ratio of 15.2, compared to higher ratios of 20.1 for Blueprint Medicines and 18.3 for Mirati Therapeutics, indicating potential upside.

View full answer

Is Revolution Medicines, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Revolution Medicines, Inc. shows a bullish trend supported by strong weekly indicators, despite mixed monthly signals, having outperformed the S&P 500 in the past month but underperformed over the past year.

View full answer

Compare Revolution Medicines, Inc. with Similar Stocks

USANA Health Sciences, Inc.Nature's Sunshine Products, Inc.Chromadex Corp.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 19,619 Million (Mid Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.20

Return on Equity

-59.99%

Price to Book

12.29

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-454 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

46.18%

6 Months

133.58%

1 Year

278.41%

2 Years

266.54%

3 Years

485.5%

4 Years

738.29%

5 Years

382.1%

Revolution Medicines, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-254.43%

EBIT to Interest (avg)

-390.67

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

12.29

EV to EBIT

-17.07

EV to EBITDA

-17.33

EV to Capital Employed

-55.62

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-59.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 81 Schemes (33.69%)

Foreign Institutions

Held by 203 Foreign Institutions (21.31%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -24.36% vs -19.56% in Dec 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-440.70",
          "val2": "-356.90",
          "chgp": "-23.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.20",
          "val2": "11.90",
          "chgp": "2.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.80",
          "val2": "-12.60",
          "chgp": "-25.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-453.80",
          "val2": "-364.90",
          "chgp": "-24.36%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -88.52% vs -37.51% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1,165.80",
          "val2": "-677.70",
          "chgp": "-72.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "24.20",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-15.40",
          "val2": "4.30",
          "chgp": "-458.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,131.30",
          "val2": "-600.10",
          "chgp": "-88.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ

Mar'26

Dec'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-440.70

-356.90

-23.48%

Interest

12.20

11.90

2.52%

Exceptional Items

-15.80

-12.60

-25.40%

Consolidate Net Profit

-453.80

-364.90

-24.36%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Dec 2025

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2026 is -24.36% vs -19.56% in Dec 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1,165.80

-677.70

-72.02%

Interest

24.20

0.00

Exceptional Items

-15.40

4.30

-458.14%

Consolidate Net Profit

-1,131.30

-600.10

-88.52%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs -100.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -88.52% vs -37.51% in Dec 2024

All Annual Results

Company CV

About Revolution Medicines, Inc.

Revolution Medicines, Inc.

Pharmaceuticals & Biotechnology

Revolution Medicines, Inc. is a clinical-stage precision oncology company. The Company is focused on developing targeted therapies to inhibit elusive frontier targets within notorious growth and survival pathways, with particular emphasis on the renin angiotensin system (RAS) and mammalian target of rapamycin (mTOR) signaling pathways. The Company’s pipeline includes RMC-4630, a clinical-stage drug candidate that is designed to selectively inhibit the activity of SHP2. Additionally, the Company is developing a portfolio of inhibitors of other key frontier oncology targets within the notorious RAS pathway, as well as the related mTOR signaling cascade. These include inhibitors of multiple mutant RAS proteins and son of sevenless homolog one (SOS1), as well as RMC-5552. RMC-5552 is a selective inhibitor of mammalian target of rapamycin complex one (mTORC1) that is designed to preserve the tumor suppressive activity.

Company Coordinates

Company Details

700 Saginaw Dr , REDWOOD CITY CA : 94063-4752

Tel: 1 415 7663638

http://revolutionmedicines.com/

Registrar Details